PARP inhibitors: Mechanism of action and their potential role in the prevention and treatment of cancer

Drugs

Volumn 72, Issue 12, 2012, Pages 1579-1590

  Basu, Bristi ^a,b   Sandhu, Shahneen K ^a,b   De Bono, Johann S ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Antineoplastics; Biomarkers; BMN 673; Breast cancer; CEP 9722; Iniparib; MK 4827; Olaparib; Ovarian cancer; Pharmacology; Polymerase inhibitors; Rucaparib phosphate; Veliparib

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BMN 673; CARBOPLATIN; CEDIRANIB; CEP 9722; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; INIPARIB; IRINOTECAN; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; OXALIPLATIN; PACLITAXEL; PLATINUM; RUCAPARIB; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CANCER; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CARCINOMATOUS PERITONITIS; CARCINOSARCOMA; CENTRAL NERVOUS SYSTEM TUMOR; COLORECTAL CANCER; DNA REPAIR; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE GENITAL TRACT TUMOR; GENE MUTATION; GENETIC SUSCEPTIBILITY; GLIOBLASTOMA; GLIOMA; GYNECOLOGIC CANCER; HETEROZYGOTE; HUMAN; LIVER CELL CARCINOMA; LONG TERM CARE; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MONOTHERAPY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PATIENT SELECTION; PERITONEUM CANCER; PROSTATE CANCER; SOLID TUMOR; STOMACH CANCER; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; UTERINE CERVIX CANCER; UTERINE TUBE TUMOR; UTERUS CARCINOMA;

ANIMALS; BRCA1 PROTEIN; BRCA2 PROTEIN; ENZYME INHIBITORS; HUMANS; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84864687912     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11635510-000000000-00000     Document Type: Article

References (81)

1. Chambon P, Weill JD, Mandel P. Nicotinamide mono-nucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 1963 Apr 2; 11: 39-43
2. Otto H, Reche PA, Bazan F, et al. In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC Genomics 2005; 6: 139
3. de la Lastra CA, Villegas I, Sanchez-Fidalgo S. Poly(ADP- ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications. Curr Pharm Des 2007; 13 (9): 933-62 (Pubitemid 46628291)
4. Langelier MF, Planck JL, Roy S, et al. Crystal structures ofpoly(ADP-ribose) polymerase-1 (PARP-1) zinc fingers bound to DNA: structural and functional insights into DNA-dependent PARP-1 activity. J Biol Chem 2011 Mar 25; 286 (12): 10690-701
5. Chalmers A, Johnston P, Woodcock M, et al. PARP-1, PARP-2, and the cellular response to low doses ofionizing radiation. Int J Radiat Oncol Biol Phys 2004 Feb 1; 58 (2): 410-9 (Pubitemid 38142466)
6. Curtin NJ. PARP inhibitors for cancer therapy. Expert Rev Mol Med 2005 Mar 15; 7 (4): 1-20
7. Hoeijmakers JH. Genome maintenance mechanisms for preventingcancer. Nature2001 May 17; 411 (6835): 366-74
8. Ratnam K, Low JA. Current development of clinical in- hibitors ofpoly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007 Mar 1; 13 (5): 1383-8 (Pubitemid 46450426)
9. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008 Aug 1; 26 (22): 3785-90
10. Yap TA, Sandhu SK, Carden CP, et al. Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 2011 Jan-Feb; 61 (1): 31-49
11. D'Amours D, Desnoyers S, D'Silva I, et al. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear func-tions. Biochem J 1999 Sep 1; 342 (Pt 2): 249-68 (Pubitemid 29425344)
12. Rankin PW, Jacobson EL, Benjamin RC, et al. Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo. J Biol Chem 1989 Mar 15; 264 (8): 4312-7 (Pubitemid 19081328)
13. Southan GJ, Szabo C. Poly(ADP-ribose) polymerase in- hibitors. Curr Med Chem 2003 Feb; 10 (4): 321-40
14. Papeo G, Forte B, Orsini P, et al. Poly(ADP-ribose) poly- merase inhibition in cancer therapy: are we close to ma-turity? Exp Opin Ther Patents 2009 Oct; 19 (10): 1377-400
15. Moore J, Keyt B, Burnler J, et al. Treatment ofcancer. US patent application publication US2008/0103104 A1. 2008
16. Liu X, Shi Y, Maag DX, et al. Iniparib non-selectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012 Jan 15; 18 (2): 510-23
17. Fong PC, Boss DS, Yap TA, et al. Inhibition ofpoly(ADP- ribose) polymerase in tumors from BRCA mutation car-riers. N Engl J Med 2009 Jul 9; 361 (2): 123-34
18. Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009 Jun 1; 27 (16): 2705-11
19. Plummer R, Jones C, Middleton M, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with ad-vanced solid tumors. Clin Cancer Res 2008 Dec 1; 14 (23): 7917-23
20. Kaelin Jr WG. The concept of synthetic lethality in the context ofanticancer therapy. Nat Rev Cancer 2005 Sep; 5 (9): 689-98 (Pubitemid 41486362)
21. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005 Apr 14; 434 (7035): 913-7 (Pubitemid 40559005)
22. Helleday T, Bryant HE, Schultz N. Poly(ADP-ribose) poly- merase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 2005 Sep; 4 (9): 1176-8 (Pubitemid 41365386)
23. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strat-egy. Nature 2005 Apr 14; 434 (7035): 917-21 (Pubitemid 40559006)
24. Audeh MW, Carmichael J, Penson RT, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010 Jul 24; 376 (9737): 245-51
25. Tutt A, Robson M, Garber JE, et al. Oralpoly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010 Jul 24; 376 (9737): 235-44
26. Plummer ER. Inhibition ofpoly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol 2006 Aug; 6 (4): 364-8
27. Kummar S, Chen A, Ji J, et al. Phase I study ofPARP in- hibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 2011 Sep 1; 71 (17): 5626-34
28. Giaccone G, Rajan A, Kelly R, et al. A phase I combination study ofolaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors ab-stract. J Clin Oncol 2010; 28 (15S): 3027A
29. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011 Jan 20; 364 (3): 205-14
30. AstraZeneca. AstraZeneca updates on olaparib and TC- 5214 development programmes media release. 2011 Dec 20 online. Available from URL: http://www.astrazeneca. com/Media/Press-releases/Article/20111220-az-updates-ol aparib-TC5214-development Accessed 2012 Jul 16
31. Calabrese CR, Almassy R, Barton S, et al. Anticancer che- mosensitization and radiosensitization by the novel poly (ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004 Jan 7; 96 (1): 56-67 (Pubitemid 38180960)
32. Nowsheen S, Bonner JA, Yang ES. The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol 2011 Jun; 99 (3): 331-8
33. Senra JM, Telfer BA, Cherry KE, et al. Inhibition ofPARP- 1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther 2011 Oct; 10 (10): 1949-58
34. Wang L, Mason KA, Ang KK, et al. MK-4827, a PARP-1/- 2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. Epub 2011 Nov 30
35. Blakeley J, Ye X, Grossman S, et al. Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma abstract. J Clin Oncol 2010; 28 (15S): 2012A
36. Dungey FA, Loser DA, Chalmers AJ. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Rad Oncol Biol Phys 2008 Nov 15; 72 (4): 1188-97
37. Chalmers AJ. Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors. Anticancer Agents Med Chem 2010 Sep; 10 (7): 520-33
38. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006 Aug 15; 66 (16): 8109-15 (Pubitemid 44299177)
39. Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP in-hibitors. EMBO Mol Med 2009 Sep; 1 (6-7): 315-22
40. Weston VJ, Oldreive CE, Skowronska A, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 2010 Nov 25; 116 (22): 4578-87
41. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000 Aug 17; 406 (6797): 747-52
42. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004 Aug 15; 10 (16): 5367-74 (Pubitemid 39100473)
43. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006 Sep 25; 25 (43): 5846-53 (Pubitemid 44453440)
44. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dys- function in sporadic basal-like breast cancer. Oncogene 2007 Mar 29; 26 (14): 2126-32 (Pubitemid 46514749)
45. Thompson ME, Jensen RA, Obermiller PS, et al. Decreased expression ofBRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995 Apr; 9 (4): 444-50
46. Byrski T, Gronwald J, Huzarski T, et al. Pathologic com- plete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010 Jan 20; 28 (3): 375-9
47. Gelmon K, Hirte H, Robidoux A, et al. Can we define tu- mors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer abstract no. 3002. J Clin Oncol 2010; 28 (15 Suppl.)
48. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differ-entiated ovarian carcinoma or triple-negative breast can-cer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011 Sep; 12 (9): 852-61
49. Bouwman P, Aly A, Escandell JM, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010 Jun; 17 (6): 688-95
50. Bunting SF, Callen E, Wong N, et al. 53BP1 inhibits homo- logous recombination in Brca1-deficient cells by blocking resection of DNA breaks.Cell2010 Apr 16; 141 (2):243-54
51. Cheung HW, Cowley GS, Weir BA, et al. Systematic In Vestigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A 2011 Jul 26; 108 (30): 12372-7
52. Cancer Genome Atlas Research Network. Integrated geno- mic analyses of ovarian carcinoma. Nature 2011 Jun 29; 474 (7353): 609-15
53. Ledermann J, Harter P, Gourley C, et al. Olaparib main- tenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012 Apr 12; 366 (15): 1382-92
54. Zhao W, Duan W, Leon M, et al. Targeting fanconi anemia (FA) repair pathway deficiency for treatment with PARP inhibitors abstract. J Clin Oncol2010; 28 (15S): TPS168A
55. Sanchez EV, Chow A, Raskin L, et al. Preclinical testing of the PARP inhibitor ABT-888 in microsatellite instable colorectal cancer abstract. J Clin Oncol 2009; 27 (15S): 11028A
56. Williamson CT, Muzik H, Turhan AG, et al. ATM defi- ciency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 2010 Feb; 9 (2): 347-57
57. Gaymes TJ, Shall S, Farzaneh F, et al. Chromosomal in- stability syndromes are sensitive to poly ADP-ribose polymerase inhibitors. Haematologica 2008 Dec; 93 (12): 1886-9
58. Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010 Oct 13; 2 (53): 53ra75
59. Fraser M, Zhao H, Luoto KR, et al. PTEN deletion in prostatecancer cells doesnotassociatewithloss ofRAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res 2012 Feb 15; 18 (4): 1015-27
60. Brenner JC, Ateeq B, Li Y, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011 May 17; 19 (5): 664-78
61. Brenner JC, Feng FY, Han S, et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res 2012 Apr 1; 72 (7): 1608-13
62. Iorns E, Lord CJ, Turner N, et al. Utilizing RNA inter- ference to enhance cancer drug discovery. Nat Rev Drug Disc 2007 Jul; 6 (7): 556-68 (Pubitemid 47019444)
63. Graeser M, McCarthy A, Lord CJ, et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010 Dec 15; 16 (24): 6159-68
64. Asakawa H, Koizumi H, Koike A, et al. Prediction ofbreast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast Cancer Res 2010; 12 (2): R17
65. Mukhopadhyay A, Elattar A, Cerbinskaite A, et al. DevelOpment of a functional assay for homologous recombina-tion status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) poly-merase inhibitors. Clin Cancer Res 2010 Apr 15; 16 (8): 2344-51
66. Gottipati P, Vischioni B, Schultz N, et al. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombina-tion-defective cells. Cancer Res 2010 Jul 1; 70 (13): 5389-98
67. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in me-tastatic castration-resistant prostate cancer. Clin Cancer Res 2008 Oct 1; 14 (19): 6302-9
68. Bednarz N, Eltze E, Semjonow A, et al. BRCA1 loss pre- existing in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood. Clin Cancer Res 2010 Jul 1; 16 (13): 3340-8
69. Wang LH, Pfister TD, Parchment RE, et al. Monitoring drug-induced gammaH2AX as a pharmacodynamic bio-marker in individual circulating tumor cells. Clin Cancer Res 2010 Feb 1; 16 (3): 1073-84
70. Norquist B, Wurz KA, Pennil CC, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy re-sistance in hereditary ovarian carcinomas. J Clin Oncol 2011 Aug 1; 29 (22): 3008-15
71. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose poly- merase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free in-terval. J Clin Oncol 2010 May 20; 28 (15): 2512-9
72. Edwards SL, Brough R, Lord CJ, et al. Resistance to ther- apy caused by intragenic deletion in BRCA2. Nature 2008 Feb 28; 451 (7182): 1111-5 (Pubitemid 351317441)
73. Sakai W, Swisher EM, Karlan BY, et al. Secondary muta- tions as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008 Feb 28; 451 (7182): 1116-20 (Pubitemid 351317449)
74. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity ofBRCA1-deficientmammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008 Nov 4; 105 (44): 17079-84
75. Chiarugi A. A snapshot of chemoresistance to PARP in- hibitors. Trends Pharmacol Sci 2012 Jan; 33 (1): 42-8
76. Schild D, Wiese C. Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse geno-mic instability. Nucleic Acids Res 2010 Mar; 38 (4): 1061-70
77. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008 Aug; 8 (4): 363-9
78. Hay T, Matthews JR, Pietzka L, et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009 May 1; 69 (9): 3850-5
79. Drew Y, Plummer R. PARP inhibitors in cancer therapy: two modes ofattack on the cancer cell widening the clinical applications. Drug Resist Updat 2009 Dec; 12 (6): 153-6
80. Tong WM, Ohgaki H, Huang H, et al. Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice. Am J Pathol 2003 Jan; 162 (1): 343-52 (Pubitemid 36042016)
81. Devalaraja-Narashimha K, Padanilam BJ. PARP1 deficiency exacerbates diet-induced obesity in mice. J Endocrinol 2010 Jun; 205 (3): 243-52